Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes

European Journal of Clinical Pharmacology

Volumn 52, Issue 1, 1997, Pages 41-47

  Yue, Q Y ^a   Sawe J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

codeine; human liver microsomes; N demethylation; O demethylation

Indexed keywords

AMITRIPTYLINE; CODEINE; CYCLOSPORIN A; CYTOCHROME P450 ISOENZYME; DEXTROPROPOXYPHENE; ERYTHROMYCIN; LIDOCAINE; METHADONE; METOPROLOL; MIDAZOLAM; QUINIDINE; THEOPHYLLINE; THIORIDAZINE;

ADULT; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

CODEINE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES;

EID: 0030887069     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050247     Document Type: Article

References (55)

1. Alván G, von Bahr C, Seideman P, Sjöqvist F (1982) High plasma concentrations of β-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet i: 333
2. Alván G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533-537
3. Back DJ, Tjia JF (1991) Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32: 624-626
4. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA (1989) Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 46: 521-527
5. Bertilsson L, Meese CO, Yue QY, Dahl ML, Ingelman-Sundberg M, Johansson I, Säwe J, Eichelbaum M (1993) Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes. Pharmacogenetics 3: 94-100
6. Boobis AR, Murray S, Kahn GC, Robertz GM, Davies DS (1983) Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol 2: 474-481
7. Brinn R, Brosen K, Gram LF, Haghfelt T, Otton SV (1986) Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol 22: 194-197
8. Brosen K, Gram LF (1989) Clinical significance of the sparteine/ debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36: 537-547
9. Brøsen K, Gram LF, Haghfelt T, Bertilsson L (1987) Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 60: 312 -314
10. Chen ZR, Somogyi AA, Bochner F (1988) Polymorphic O-demethylation of codeine. Lancet ii: 914-915
11. Combalbert J, Fahre I, Fabre G, Dalet I, Derancourt J, Cano JP, Maurel P (1989) Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Disp 17: 197 -207
12. Dahlqvist R, Bertilsson L, Birkett DJ, Eichelbaum M, Säwe J, Sjöqvist F (1984) Theophylline mtabolism in relation to antipyrine, debrisoquine, and sparteine metabolism. Clin Pharmacol Ther 35: 815-821
13. Dayer P, Desmeules J, Leemann T, Striberni R (1988) Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufl). Biochem Biophys Res Commun 152: 411-416
14. Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism clinical aspects. Pharmacol Ther 46: 377-394
15. Gorski JC, Jones DR, Wrighton SA, Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P4503A (CYP3A) subfamily. Biochem Pharmacol 48: 173-182
16. Gu L, Gonzalez FJ, Kalow W, Tang BK (1992) Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A and CYP2E1. Pharmacogenetics 2: 73-77
17. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ (1986a) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism, J Biol Chem 261: 5051-5060
18. Guengerich FP, Meuller-Enoch D, Blair IA (1986b) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30:287-295
19. Inaba T, Tyndale RE, Mahon WA (1986) Quinidine: Potent inhibition of sparteine and debrisoquine oxidation in vivo. Br J Clin Phamacol 22: 199 -200
20. Jacqz-Aigrain E, Funck-Bretano C, Cresteil T (1993) CYP2D6-and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3: 197 -204
21. Johansson I, Yue QY, Dahl ML, Heim M, Säwe J, Bertilsson L, Meyer UA, Sjöqvist F, Ingelman-Sundberg M (1991) Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metablism of debrisoquine and codeine. Eur J Clin Pharmacol 40: 553 -556
22. Johansson I, Oscarsson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P450 2D locus. Characterization of variant CYP2D6-genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46: 452-459
23. Kalow W, Bertilsson L (1994) Interethnic factors affecting drug response. In: Testa B and Meyer UA Advances in drug research, vol 25. Academic Press, p 153
24. Kitada M, Kamataki T, Itahshi K, Rikihisa T, Kato R, Kanakubo Y (1987) P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 α-hydroxylase of dehydroepiandrosterone 3-sulphate. J Biol Chem 262: 13534-13537
25. Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P (1990) Evidence for altered desiprasmine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse 16: 329 -336
26. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM (1976) Rifampicin-induced methadone withdrawal. N Engl J Med 294: 1104-1106
27. Kronback T, Fischer V, Meyer UA (1988) Cyclosporine metabolism in human liver: Identification of a cytochrome P-450 III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43: 630 -635
28. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazoloam by human liver cytochrome P-450 IIIA4. Mol Pharmacol 36: 89 -96
29. Ladona MG, Lindström B, Thyr C, Dun-Ren P, Rane A (1991) Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br J Clin Pharmacol 32: 295 -302
30. Leemann T, Dayer P, Meyer UA (1986) Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 29: 739 -741
31. Maany I, Dhopesh V, Arndt IO, Burke W, Woody G, O'Brien CP (1989) Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatr 146: 1611 -1613
32. Mellström B, Säwe J, Bertilsson L, Sjöqvist F (1986) Amitriptyline metabolism: association with debrisoquine hydroxylation in nonsmokers. Clin Pharmacol Ther 39: 369 -371
33. Minder EI, Meier PJ, Muller HK, Minder C, Meyer UA (1984) Bufuralol metabollism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation. Eur J Clin Invest 14: 184-189
34. Mikus G, Somogyi AA, Bochner F, Eichelbaum M (1991 ) Codeine O-demethylation: Rat strain differences and the effects of inhibitors. Biochem Pharmacol 41: 757 -762
35. Mortimer O, Persson K, Ladona MG, Spalding D, Zanger UM, Meyer UA, Rane A (1990) Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: Relationship to the presence of immunoidentified cytochrome P-450IID1. Clin Pharmacol Ther 47: 27-35
36. Nielsen F, Rosholm JU, Brosen K (1995) Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. Eur J Clin Pharmacol 48: 501- 504
37. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53: 298-305
38. Otton SV. Inaba T, Kalow W (1984) Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs, 34: 74-80
39. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, Maurel P (1990) Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18: 595-606
40. Schellens JH, Soons PA, Breimer DD (1988) Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 37: 2507-2510
41. Steiner E, Dumont E, Spina E, Dahlqvist R (1988) Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther 43: 577-581
42. Svensson JO, Yue QY, Säwe J (1995) Determination of codeine and metabolites in plasma and urine using ion-pair high-per-formance liquid chromatography. J Chromatogr 674: 49-55
43. Trivier JM, Libersa C, Belloc C, Lhermitte M (1993) Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report). Life Sci 52: 91-96
44. von Bahr C, Groth CG, Jansson H, Lundgren G, Lind M, Glaumann H (1980) Drug metabolism in human liver in vitro: Establishment of a human liver bank. Clin Pharmacol Ther 27: 711-725
45. n Bahr C, Spina E, Birgersson C, Ericsson Ö, Göransson M, Henthorn T, Sjöqvist F (1985) Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 14: 2501-2505
46. von Bahr C, Movin G, Nordin C, Lidén A, Hammarlund-Udenaes M, Hedberg A, Ringh H, Sjöqvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 49: 234-240
47. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS (1989) Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 83: 688-697
48. Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Praker GA, Guzelian PS (1985) Identification of an inducible form of cytochrome P-450 in human liver. Proc. Not. Acad. Sci (USA) 82: 6310-6314
49. Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W, Sellers EM (1993) Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 35: 30-34
50. Yee GC, McGuire TR (1990) Pharmacokinetic drug interactions with cyclosporin (Part 1) clin pharmacokin 19: 319-332
51. Yue QY, Svensson JO, Aim C, Sjöqvist F, Säwe J (1989a) Inter-individual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol 28: 629-637
52. Yue QY, Svensson JO, Aim C, Sjöqvist F, Säwe J (1989b) Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol 28: 639-645
53. Yue QY, Bertilsson L, Dahl-Puustinen ML, Säwe J, Sjöqvist F, Johansson I, Ingelman-Sundberg M (1989c) Dissociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Letter to the Lancet ii: 870
54. Yue QY, von Bahr C, Säwe J (1990) Glucuronidation of codeine and morphine in human liver and kidney microsomes. Effect of inhibitors. Pharmacol Toxicol 66: 221-226
55. Yue QY, Tomson T, Säwe J (1994) Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics 4: 193-198